Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17122185 | Ground, Anti-radiation supplement | December 2020 | March 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17122278 | Launch, Anti-radiation supplement | December 2020 | August 2023 | Abandon | 32 | 1 | 0 | No | No |
| 17116337 | METHOD FOR PRODUCING NATURAL ANTIMICROBIAL SUBSTANCE AND ANTIMICROBIAL COMPOSITION COMPRISING NATURAL ANTIMICROBIAL SUBSTANCE PRODUCED BY THE SAME | December 2020 | July 2023 | Abandon | 32 | 1 | 1 | No | No |
| 16972105 | Cellularised Dressing and Method for Producing Same | December 2020 | May 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17108114 | VAGINAL COMPOSITION AND USE THEREOF | December 2020 | February 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 15734027 | VASCULAR STENT WITH ANTITHROMBOTIC PROPERTIES | December 2020 | March 2024 | Allow | 40 | 1 | 1 | No | No |
| 17105780 | POROUS FOAMS DERIVED FROM EXTRACELLULAR MATRIX, POROUS FOAM ECM MEDICAL DEVICES, AND METHODS OF USE AND MAKING THEREOF | November 2020 | January 2024 | Allow | 38 | 3 | 1 | Yes | No |
| 17105536 | MANUFACTURING METHOD OF HERBAL MEDICINE PROCESSED FOOD | November 2020 | June 2022 | Allow | 19 | 1 | 0 | No | No |
| 17102461 | BIOCIDE-ENCAPSULATED MICROCAPSULE FOR USE IN PAINT | November 2020 | June 2024 | Abandon | 42 | 1 | 1 | Yes | No |
| 17102837 | METHODS OF IMPROVING MYOCARDIAL PERFORMANCE IN FONTAN PATIENTS USING UDENAFIL COMPOSITIONS | November 2020 | September 2022 | Abandon | 22 | 2 | 0 | No | No |
| 17057578 | TAHITI VANILLA EXTRACT AND 4-[(1E,3S)-3-ETHENYL-3,7-DIMETHYLOCTA-1,6-DIENYL]PHENOL FOR COMBATTING CUTANEOUS AGEING | November 2020 | April 2023 | Abandon | 29 | 1 | 1 | No | No |
| 17091234 | ANTIVIRAL COMPOSITION HAVING ANTIVIRAL ACTIVITY AGAINST CORONAVIRUS AND VARIANT VIRUSES THEREOF | November 2020 | May 2023 | Abandon | 30 | 0 | 1 | No | No |
| 17090931 | METHOD FOR TREATING PSORIASIS | November 2020 | September 2022 | Allow | 22 | 1 | 0 | No | No |
| 17085148 | METHOD FOR IMPROVING SLEEP ONSET AND SLEEP MAINTENANCE, METHOD FOR REDUCING STRESS AND IMPROVING RELAXATION, METHOD FOR IMPROVING PERFORMANCE AND CONCENTRATION, AND METHOD FOR IMPROVING RESTING EFFECT AND PROMOTING RECOVERY FROM FATIGUE | October 2020 | September 2023 | Abandon | 35 | 2 | 1 | Yes | No |
| 17049867 | CELL SHEET FOR TRANSPLANTATION INTO LIVING BODY AND METHOD FOR PRODUCING SAME | October 2020 | June 2024 | Allow | 44 | 1 | 1 | No | No |
| 17041795 | TRADITIONAL CHINESE MEDICINE COMPOSITION FOR PREVENTING AND/OR TREATING ISCHEMIC REPERFUSION INJURY | September 2020 | April 2023 | Abandon | 30 | 2 | 1 | No | No |
| 17019402 | METHOD OF TREATING T CELL LYMPHOMAS | September 2020 | September 2022 | Allow | 24 | 1 | 0 | No | No |
| 17020674 | METHODS OF IMPROVING MYOCARDIAL PERFORMANCE IN FONTAN PATIENTS USING UDENAFIL COMPOSITIONS | September 2020 | August 2024 | Abandon | 47 | 2 | 0 | No | No |
| 17017876 | Antioxidant, Antibacterial Or Anti-Inflammatory Pharmaceutical Composition Containing Scutellaria Baicalensis Extract And Magnolia Officinalis Extract As Active Ingredients | September 2020 | October 2022 | Abandon | 25 | 1 | 0 | No | No |
| 16995903 | METHOD FOR TREATING A TUBERCULOUS PROSTATITIS SIDE EFFECT CAUSED BY BCG PERFUSION THERAPY FOR BLADDER CANCER | August 2020 | February 2022 | Allow | 18 | 1 | 0 | No | No |
| 16969410 | COMBINATION OF RHODIOLA AND ASTRAGALUS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | August 2020 | June 2023 | Allow | 34 | 2 | 1 | Yes | No |
| 16968518 | FORMULATION AND METHOD OF USE | August 2020 | September 2022 | Abandon | 26 | 0 | 1 | No | No |
| 16983543 | COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS | August 2020 | June 2022 | Abandon | 23 | 1 | 0 | No | No |
| 16929745 | NAIL COMPOSITION CONTAINING ADHESIVE AGENT, PRIMARY FILM FORMER AND PLASTICIZER | July 2020 | May 2022 | Allow | 22 | 2 | 0 | No | No |
| 16957432 | A MANUFACTURING METHOD OF AN HERBAL MEDICINAL TABLET FORMULATION FOR TREATING OBESITY WHICH CAN BE PRESCRIBED BASED ON SASANG CONSTITUTIONAL MEDICINE | June 2020 | September 2022 | Allow | 27 | 2 | 0 | No | No |
| 16957410 | HERBAL MEDICINAL TABLET FORMULATION FOR TREATING OBESITY WHICH CAN BE PRESCRIBED BASED ON SASANG CONSTITUTIONAL MEDICINE | June 2020 | May 2022 | Allow | 23 | 2 | 0 | No | No |
| 16889826 | SUSTAINED-RELEASE DRUG CARRIER COMPOSITION | June 2020 | July 2022 | Abandon | 25 | 1 | 0 | No | No |
| 16768819 | A 3D BIOPRINTED SCAR TISSUE MODEL | June 2020 | June 2023 | Allow | 36 | 1 | 1 | No | No |
| 16764564 | USE OF MAGNOLIA, JUNIPER OR VIOLET ABSOLUTE IN COSMETICS FOR DEPIGMENTING THE SKIN | May 2020 | March 2023 | Allow | 34 | 2 | 0 | Yes | No |
| 16874525 | DISINFECTANTS WITH IODINE AND COPPER COMPLEXES FOR USE AGAINST CORONAVIRUS | May 2020 | May 2022 | Allow | 27 | 2 | 1 | Yes | Yes |
| 16762531 | POSITIONAL STABILIZATION OF TISSUE-IMPLANTED MEDICAL DEVICES | May 2020 | December 2023 | Allow | 43 | 2 | 1 | Yes | No |
| 16869807 | Web Material and Method for Making Same | May 2020 | May 2024 | Abandon | 48 | 5 | 0 | Yes | No |
| 16861752 | METHODS FOR TREATING DIARRHEA PREDOMINANT IRRITABLE BOWEL SYNDROME | April 2020 | April 2022 | Abandon | 23 | 1 | 0 | No | No |
| 16842059 | POSTERIOR SEGMENT DRUG DELIVERY | April 2020 | December 2022 | Allow | 32 | 1 | 1 | No | No |
| 16817856 | Citrus Fruit Extract-Mediated Synthesis of Tellurium Nanomaterials Having Biomedical Applications | March 2020 | October 2022 | Allow | 31 | 1 | 1 | Yes | No |
| 16813864 | SUSTAINED RELEASE FORMULATION COMPRISING OCTREOTIDE AND TWO OR MORE POLYLACTIDE-CO-GLYCOLIDE POLYMERS | March 2020 | June 2022 | Abandon | 27 | 1 | 1 | No | No |
| 16811849 | Oriental Medicine Composition Effective For Thyroid Hormone Level Normalization | March 2020 | June 2022 | Allow | 27 | 2 | 0 | No | No |
| 16808726 | Composition for treatment and management of Dementia and Cognitive dysfunction and method of preparation thereof | March 2020 | June 2022 | Allow | 28 | 1 | 1 | No | No |
| 16796893 | PHARMACEUTICAL COMPOSITION AND EXTRACT OF DENDROBII CAULIS WITH EYE CARE EFFECT AND USES OF PREPARING THE SAME THEREOF | February 2020 | October 2022 | Allow | 32 | 2 | 1 | No | No |
| 16638546 | METHODS OF DIAGNOSING AND TREATING DRY EYE SYNDROME AND COMPOSITIONS FOR TREATING A HUMAN EYE | February 2020 | February 2023 | Allow | 36 | 3 | 1 | Yes | No |
| 16781822 | USES OF FERMENTATION PRODUCT OF LOTUS LEAF-HAWTHORN EXTRACT AND ITS ACTIVE INGREDIENT IN INHIBITING THE FORMATION OF FAT | February 2020 | November 2022 | Abandon | 34 | 2 | 1 | No | No |
| 16748054 | PRODUCTION OF MATERIALS HAVING AN ANISOTROPIC STRUCTURE | January 2020 | April 2023 | Allow | 39 | 2 | 1 | Yes | Yes |
| 16741729 | ALL-NATURAL TOPICAL PAIN RELIEF OINTMENT | January 2020 | August 2022 | Abandon | 31 | 1 | 1 | No | No |
| 16630745 | NEW COMPOSITION FOR STRAIGHTENING HAIR | January 2020 | August 2022 | Allow | 31 | 2 | 1 | Yes | No |
| 16628711 | A COATED COSTUS COMPOSITION ENRICHED WITH TRITERPENOIDS AND A METHOD OF PREPARATION OF THE SAME | January 2020 | May 2022 | Abandon | 28 | 0 | 1 | No | No |
| 16733985 | COMBINATION THERAPY OF PHOSPHATE BINDERS AND VITAMIN K | January 2020 | June 2024 | Abandon | 53 | 6 | 1 | No | No |
| 16623774 | CURCUMIN CARBON QUANTUM DOTS AND USE THEREOF | December 2019 | August 2022 | Allow | 32 | 1 | 1 | No | No |
| 16602717 | Zen roller | November 2019 | January 2023 | Allow | 38 | 1 | 0 | Yes | No |
| 16682528 | TABLET COMPRISING SEPARATE BINDER AND ERYTHRITOL | November 2019 | May 2022 | Allow | 30 | 2 | 0 | No | No |
| 16682169 | ORAL DELIVERY VEHICLE CONTAINING FLAVORING AGENTS | November 2019 | April 2022 | Allow | 29 | 2 | 0 | No | No |
| 16677431 | AMANTADINE COMPOSITIONS AND PREPARATIONS THEREOF | November 2019 | May 2021 | Allow | 19 | 3 | 0 | Yes | No |
| 16659595 | CHEMICALLY STABLE COMPOSITIONS OF A PHARMACEUTICAL ACTIVE AGENT IN A MULTI-CHAMBERED DELIVERY SYSTEM FOR MUCOSAL DELIVERY | October 2019 | December 2021 | Abandon | 26 | 0 | 1 | No | No |
| 16653416 | CANNABINOID AND SUGAR ALCOHOL COMPLEX, METHODS TO MAKE AND USE | October 2019 | December 2022 | Allow | 39 | 3 | 0 | No | No |
| 16604375 | SPORODERM-REMOVED GANODERMA LUCIDUM SPORE POWDER, GRANULE AND PREPARATION METHOD THEREOF | October 2019 | December 2022 | Allow | 39 | 2 | 1 | No | No |
| 16500446 | RISPERIDONE-CONTAINING PATCH | October 2019 | April 2022 | Allow | 30 | 1 | 1 | No | No |
| 16566721 | AGGREGATING MICROPARTICLES FOR MEDICAL THERAPY | September 2019 | January 2022 | Allow | 28 | 1 | 1 | No | No |
| 16566724 | AGGREGATING MICROPARTICLES FOR MEDICAL THERAPY | September 2019 | September 2022 | Allow | 36 | 2 | 1 | No | No |
| 16492473 | SYNERGISTIC HERBAL COMPOSITIONS FOR TESTOSTERONE BOOSTING | September 2019 | February 2023 | Allow | 41 | 1 | 1 | No | No |
| 16544672 | APPARATUS AND PROCESS FOR ENCAPSULATING CAPSULES OR OTHER SOLID DOSAGE FORMS WITHIN CAPSULES | August 2019 | September 2023 | Abandon | 49 | 4 | 1 | Yes | No |
| 16540142 | Dressing | August 2019 | June 2023 | Allow | 46 | 4 | 0 | Yes | Yes |
| 16518154 | HAND SANITIZER AND METHOD OF MAKING THE SAME | July 2019 | October 2022 | Allow | 38 | 3 | 1 | Yes | No |
| 16515405 | POLYMERIC NANOPARTICLES COMPRISING SALINOMYCIN | July 2019 | November 2023 | Abandon | 52 | 5 | 1 | Yes | No |
| 16513613 | MICROARRAY FOR DELIVERY OF THERAPEUTIC AGENT AND METHODS OF USE | July 2019 | September 2022 | Allow | 38 | 4 | 1 | No | Yes |
| 16502781 | METHODS OF DEPOSITING SILVER NANOSTRUCTURES ON TO IMPLANT SURFACES | July 2019 | September 2023 | Abandon | 51 | 3 | 1 | No | No |
| 16472156 | SOLID COSMETIC COMPOSITION WITH A MOISTURIZING EFFECT | June 2019 | September 2021 | Allow | 27 | 1 | 1 | No | No |
| 16471066 | MULTI-LAYER WOUND CARE PRODUCT WITH PERFORATED RELEASE LAYER | June 2019 | September 2019 | Allow | 3 | 0 | 0 | Yes | No |
| 16471409 | AROMATIC MIXTURE FOR REDUCING THE ODOR OR TASTE OF BIOGENIC AMINES | June 2019 | November 2022 | Abandon | 41 | 0 | 1 | No | No |
| 16443895 | METHOD OF PREPARING LIPID NANOCARRIER | June 2019 | September 2021 | Abandon | 27 | 1 | 1 | No | No |
| 16501845 | Composition For Enchanced Recovery After Surgery (ERAS) | June 2019 | May 2021 | Abandon | 23 | 1 | 0 | Yes | No |
| 16470136 | LAYERED PARTICLES AND PROCESSES THEREOF | June 2019 | December 2023 | Allow | 54 | 2 | 1 | Yes | No |
| 16441872 | DEVICE AND METHOD OF TREATING CONDITIONS ASSOCIATED WITH NEUROINFLAMMATION | June 2019 | September 2020 | Abandon | 15 | 2 | 1 | No | No |
| 16431248 | Ophthalmic Compositions and Medical Uses Thereof in Treatment of Myopia | June 2019 | May 2022 | Allow | 35 | 1 | 1 | No | No |
| 16418061 | COMPOSITIONS, METHODS OF TREATMENT, AND CONTAINERS INCLUDING COMPOSITIONS | May 2019 | May 2022 | Allow | 36 | 0 | 1 | No | No |
| 16414055 | DOSE RESPONSE, SURFACE MODIFIED NANOTUBES | May 2019 | November 2021 | Abandon | 30 | 2 | 1 | No | No |
| 16334175 | MEDICINAL AGENT-CONTAINING MOLECULAR ASSEMBLY WHICH USES AMPHIPHILIC BLOCK POLYMER | May 2019 | September 2021 | Allow | 30 | 1 | 1 | No | No |
| 16409554 | METHODS OF USING AMANTADINE COMPOSITIONS | May 2019 | May 2021 | Allow | 24 | 4 | 1 | Yes | No |
| 16409257 | SUBLINGUAL FILMS | May 2019 | March 2022 | Allow | 35 | 2 | 1 | Yes | No |
| 16347725 | FABRICATION OF AUTOLOGOUS BONE | May 2019 | August 2021 | Allow | 27 | 2 | 1 | No | No |
| 16398643 | Blood Lipids, Glucose Tolerance and Insulin Sensitivity | April 2019 | March 2022 | Abandon | 34 | 5 | 0 | No | No |
| 16345456 | ESOMEPRAZOLE-CONTAINING COMPLEX CAPSULE AND PREPARATION METHOD THEREFOR | April 2019 | March 2021 | Allow | 22 | 2 | 0 | Yes | No |
| 16392856 | FUCOIDAN-QUATERNIZED CHITOSAN NANOPARTICLES AND APPLICATION THEREOF | April 2019 | June 2021 | Allow | 25 | 2 | 1 | No | No |
| 16392995 | LIGHT ACTIVATED GASOTRANSMITTER GENERATING COMPOSITIONS | April 2019 | October 2021 | Allow | 30 | 3 | 1 | Yes | No |
| 16344086 | TREATMENT OF GYNOID LIPODYSTROPHY | April 2019 | March 2022 | Allow | 35 | 3 | 1 | No | No |
| 16340676 | NANOPARTICLE FORMULATIONS AND METHODS OF MAKING AND USING THEREOF | April 2019 | September 2021 | Abandon | 29 | 2 | 1 | No | No |
| 16374560 | EFFERVESCENT TABLETS THAT INCLUDE CRYSTALLINE SUGAR BINDER AND METHODS OF MAKING THE SAME | April 2019 | February 2021 | Allow | 22 | 3 | 1 | Yes | No |
| 16371806 | PARTICULATE COATED HYDROGEL MICROPARTICLES | April 2019 | August 2021 | Allow | 28 | 2 | 1 | No | No |
| 16334626 | SUSTAINED RELEASE FIBERS | March 2019 | March 2021 | Allow | 24 | 2 | 1 | Yes | No |
| 16333685 | METHODS FOR TREATING OR PREVENTING ORGANOPHOSPHATE POISONING | March 2019 | December 2021 | Allow | 33 | 3 | 1 | Yes | No |
| 16331508 | PLANT EXTRACT-BASED BIOLOGICALLY ACTIVE SUPPLEMENT HAVING ANTIBACTERIAL, ANTIVIRAL AND ANTIFUNGAL ACTION | March 2019 | February 2022 | Abandon | 35 | 0 | 1 | No | No |
| 16287690 | CROSSLINKED PARTICLES | February 2019 | April 2022 | Allow | 38 | 3 | 1 | Yes | No |
| 16287419 | SOLID PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PRODUCTION | February 2019 | September 2020 | Allow | 18 | 1 | 0 | No | No |
| 16281946 | SHINE CONDITIONERS | February 2019 | December 2020 | Allow | 22 | 3 | 0 | No | No |
| 16277246 | RUTHENIUM u-NITRIDO COMPLEXES AND THEIR USE AS CALCIUM UPTAKE INHIBITORS | February 2019 | June 2021 | Allow | 28 | 2 | 1 | No | No |
| 16273185 | CONSUMER PRODUCT COMPOSITIONS COMPRISING MICROCAPSULES | February 2019 | November 2020 | Abandon | 21 | 1 | 1 | No | No |
| 16321782 | COMPOSITION FOR INHIBITING SEBUM SECRETION COMPRISING PEACH SPROUT EXTRACT | January 2019 | March 2022 | Allow | 38 | 1 | 0 | No | No |
| 16246568 | DELIVERY PARTICLE | January 2019 | July 2020 | Allow | 18 | 3 | 0 | Yes | No |
| 16237207 | METHOD OF TREATING MULTIPLE SCLEROSIS | December 2018 | June 2020 | Abandon | 18 | 2 | 0 | Yes | No |
| 16313929 | PREPARATION OF CHEMOPROTECTIVE NANOPARTICLES CONTAINING TOCOTRIENOL AND METHODS OF USE THEREOF | December 2018 | March 2021 | Abandon | 26 | 1 | 1 | No | No |
| 16231166 | DRUG DELIVERY POLYMER AND USES THEREOF | December 2018 | June 2020 | Allow | 18 | 0 | 1 | No | No |
| 16231073 | METHOD OF TREATING MULTIPLE SCLEROSIS | December 2018 | August 2020 | Abandon | 19 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PARK, HAEJIN S.
With a 11.8% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 26.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner PARK, HAEJIN S works in Art Unit 1615 and has examined 567 patent applications in our dataset. With an allowance rate of 52.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.
Examiner PARK, HAEJIN S's allowance rate of 52.0% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by PARK, HAEJIN S receive 2.36 office actions before reaching final disposition. This places the examiner in the 63% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by PARK, HAEJIN S is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +42.8% benefit to allowance rate for applications examined by PARK, HAEJIN S. This interview benefit is in the 88% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 19.8% of applications are subsequently allowed. This success rate is in the 23% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 25.8% of cases where such amendments are filed. This entry rate is in the 37% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 62.2% of appeals filed. This is in the 40% percentile among all examiners. Of these withdrawals, 57.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 78.6% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.4% of allowed cases (in the 77% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.